Allied Market Research

2024

Drug Modeling Market

Drug Modeling Market Size, Share, Competitive Landscape and Trend Analysis Report by Type and by Application : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Drug modeling software is also known as drug designing software which has the potential to design novel drugs and proteins in the pharmaceutical and biotechnology field. These software’s are used for the analysis of molecular modeling of gene sequence, the 3D structure of proteins and genes.

Advancements in technology are a vital factor to fuel the market growth, with the advent of accurate and fast computational platforms has led to a reduction of time for development and discovery which acts as core factors to drive the market of drug modeling. The emergence of drug discovery failure and the evolution of three-dimensional drug discovery methods are likely to pave the way to create lucrative opportunities for the drug modeling software market in the forecast timeline.

COVID-19 Scenario Analysis:

  • The outbreak of COVID-19 is likely to have a moderate impact on the market in the forecast period. Research and development activities to identify the threat of SARS-CoV-2 virus on the patients suffering are likely to slow the market growth.
  • COVID-19 has brought about a significant burden on the healthcare industry globally, with disruption in the treatment of non-communicable diseases. Challenges exist in providing effective care.
  • Realizing the disturbing healthcare trends, governments are making efforts to provide excellent quality healthcare to patients globally.
  • Nationwide lockdowns, canceled or postponed elective surgeries, denied wound care services, rise in skin injuries may lead to a decline during the forecast timeline. However, on the flip side, the latter half of the forecast is predicted to show a drastic rise.

Top Impacting Factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis

  • Software-based methods such as structure-based vital screening, ligand interaction, molecular modeling, and molecular dynamics are predicted to be the most powerful tools for the observance and monitoring of pharmacodynamic and pharmacokinetic properties of the drug. These methods are accurate, fast, and provide excellent valuable insights into the experimental findings.    
  • Additionally, proper implementation of this technology is likely to reduce drug development costs and drug design. Traditional drug development and discovery includes multiple challenges such as high failure rates, time-consuming procedures, extensive capital. It also involves many rounds of chemical synthesis in the experimental screening of existing libraries. At present, the pharmaceutical sector is under pressure to cope with the requirements in drug discovery and research and avoid losses of drug failure.
  • Development of drug process, from the lead compound, is to be approximately 10 to 15 years along with lots of huge investment of money. According to the Pharmaceutical Research & Manufacturers of America, the cost of average research and development of a successful drug is estimated is US$ 2.6 billion. Only a minute proportion of research in the initial stages is translated into clinical studies. As a result, there is seen a rise in the research and development expenditure in the pharmaceutical industry.
  • North America is likely to dominate the market due to the very high demand for computational studies and drug discovery by software in the territory. The Asia-Pacific & Europe are predicted to drive the market growth due to a rise in awareness with an increase in disposable income with population. 

Key Benefits of the Report:

  • This study presents the analytical depiction of the global drug modeling market along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the global drug modeling market share.
  • The current market is quantitatively analyzed to highlight the global drug modeling market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market. 
  • The report provides a detailed global drug modeling market analysis based on competitive intensity and how the competition will take shape in the coming years. 

Questions Answered in the Drug Modeling Market Research Report:

  • What are the leading market players active in the drug modeling market?
  • What current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What are the projections for the future that would help in taking further strategic steps?

Report Tag: Drug Modeling Software, Drug Designing Software, 3D Structure Proteins, Genes

Drug Modeling Market Report Highlights

Aspects Details
icon_5
By Type
  • Database
  • Software
  • Others
icon_6
By Application
  • Drug Discovery and Development
  • Computational Physiological Medicine
  • Disease Modeling
  • Medical Imaging
  • Predictive Analysis of Drug Targets
  • Simulation Software
  • Cellular Simulation
  • Others
icon_7
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
icon_8
Key Market Players

Compugen Ltd, Nimbus Therapeutics, Dassault Systèmes,, Chemical Computing Group Ulc,, Genedata Ag,, Crown Bioscience Inc, Acellera Ltd., Biognos Ab, Leadscope, Inc, Schrödinger, Inc

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Drug Modeling Market

Global Opportunity Analysis and Industry Forecast, 2023-2032